Our data show that treatment with DK-13 and 14 inhibits the expression of JNK1/2/3 as well as the expression of total and phosphorylated ERK1/2 in both HER2-positive breast cancer cell lines in comparison with their controls (Figure 6 and Figure 7). This evidence concerns the gene MAPK3 and breast cancer.